For the quarter ended June 2023, Regeneron (REGN - Free Report) reported revenue of $3.16 billion, up 10.5% over the same period last year. EPS came in at $10.24, compared to $9.77 in the year-ago quarter.
The reported revenue represents a surprise of +4.77% over the Zacks Consensus Estimate of $3.01 billion. With the consensus EPS estimate being $9.92, the EPS surprise was +3.23%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Eylea (Aflibercept)- US: $1.50 billion versus $1.53 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -7.5% change.
- Revenues- Praluent (alirocumab)- US: $40.50 million compared to the $33.85 million average estimate based on five analysts. The reported number represents a change of +29.8% year over year.
- Revenues- Dupixent (dupilumab)- US: $2.11 billion compared to the $2.09 billion average estimate based on four analysts. The reported number represents a change of +33.1% year over year.
- Revenues- Eylea (Aflibercept)- ROW: $886.30 million versus $877.96 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.9% change.
- Revenues- Net product sales: $1.77 billion versus the eight-analyst average estimate of $1.75 billion. The reported number represents a year-over-year change of +1%.
- Revenues- Collaboration: $1.32 billion compared to the $1.24 billion average estimate based on seven analysts. The reported number represents a change of +26.2% year over year.
- Revenues- Other Revenue: $69.90 million versus the seven-analyst average estimate of $81.05 million. The reported number represents a year-over-year change of +18.1%.
- Revenues- Collaboration revenue- Bayer: $377 million versus the six-analyst average estimate of $375.98 million.
- Revenues- Collaboration revenue- Sanofi: $944 million versus $856.39 million estimated by six analysts on average.
- Revenues- Dupixent (dupilumab)- Total: $2.79 billion versus $2.71 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +33.4% change.
- Revenues- Eylea (Aflibercept)- Total: $2.39 billion versus the four-analyst average estimate of $2.42 billion. The reported number represents a year-over-year change of -4.2%.
- Revenues- Libtayo- Total: $210 million versus $191.42 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +48.6% change.
View all Key Company Metrics for Regeneron here>>>Shares of Regeneron have returned +2% over the past month versus the Zacks S&P 500 composite's +1.5% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
For the quarter ended June 2023, Regeneron (REGN - Free Report) reported revenue of $3.16 billion, up 10.5% over the same period last year. EPS came in at $10.24, compared to $9.77 in the year-ago quarter.
The reported revenue represents a surprise of +4.77% over the Zacks Consensus Estimate of $3.01 billion. With the consensus EPS estimate being $9.92, the EPS surprise was +3.23%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Eylea (Aflibercept)- US: $1.50 billion versus $1.53 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -7.5% change.
- Revenues- Praluent (alirocumab)- US: $40.50 million compared to the $33.85 million average estimate based on five analysts. The reported number represents a change of +29.8% year over year.
- Revenues- Dupixent (dupilumab)- US: $2.11 billion compared to the $2.09 billion average estimate based on four analysts. The reported number represents a change of +33.1% year over year.
- Revenues- Eylea (Aflibercept)- ROW: $886.30 million versus $877.96 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.9% change.
- Revenues- Net product sales: $1.77 billion versus the eight-analyst average estimate of $1.75 billion. The reported number represents a year-over-year change of +1%.
- Revenues- Collaboration: $1.32 billion compared to the $1.24 billion average estimate based on seven analysts. The reported number represents a change of +26.2% year over year.
- Revenues- Other Revenue: $69.90 million versus the seven-analyst average estimate of $81.05 million. The reported number represents a year-over-year change of +18.1%.
- Revenues- Collaboration revenue- Bayer: $377 million versus the six-analyst average estimate of $375.98 million.
- Revenues- Collaboration revenue- Sanofi: $944 million versus $856.39 million estimated by six analysts on average.
- Revenues- Dupixent (dupilumab)- Total: $2.79 billion versus $2.71 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +33.4% change.
- Revenues- Eylea (Aflibercept)- Total: $2.39 billion versus the four-analyst average estimate of $2.42 billion. The reported number represents a year-over-year change of -4.2%.
- Revenues- Libtayo- Total: $210 million versus $191.42 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +48.6% change.
View all Key Company Metrics for Regeneron here>>>Shares of Regeneron have returned +2% over the past month versus the Zacks S&P 500 composite's +1.5% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Get the latest research report on REGN - FREE